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tional and emerging cardiovascular risk factors and markers,
which can signiﬁcantly increase their cardiovascular morbidity and
mortality possibly linked to aberrations in GH status. Patients with
adult GHD present multiple different cardiovascular abnormalities.
In addition, cardiovascular risk in adult GHD is increased due to
altered body composition, abnormal lipid proﬁle, insulin resistance
and impaired glucose metabolism. Cardiovascular risk factors can
be reversed, at least partially, after GH replacement. However,
evidence on the effects of GH replacement on cardiovascular
events and mortality is too limited in adult GHD patients. Aim of
this review is to provide an at-a-glance overview of the role of the
GH/IGF-I on the cardiovascular system and the state of art of the
effects of GH replacement on cardiovascular system.
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GH is principally involved in the regulation of somatic growth, including cardiac development and
function, and exerts its effects either directly or indirectly by stimulating the production of its tissue
effector insulin-like growth factor-1 (IGF-I), which ultimately mediates GH actions on peripheral tis-
sues. In particular, GH/IGF-I axis plays an important role in cardiac growth, myocardial contractility and
vascular system. Abnormalities of the GH/IGF-I axis contribute in determining cardiovascular disease,
as suggested by clinical studies reporting an increased risk for cardiovascular morbidity and mortality
both in GH deﬁciency (GHD) and excess [1e4].
Physiological effects of GH on cardiovascular system
As reported in previous reviews, the relationship between GH/IGF-I axis and cardiovascular system
has been demonstrated by several experimental studies [4,5]. In physiological conditions, GH/IGF-I axis
exerts relevant cardiovascular actions aimed to regulate cardiac growth and myocardial contractility,
thus contributing to the maintenance of cardiac mass and function in normal adults [4]. Functional
receptors for GH and IGF-I are also expressed in blood vessels [6]. Thus GH/IGF-I axis interacts spe-
ciﬁcally with the vascular system regulating the vascular tone and the peripheral resistance [4], which
indirectly affects cardiac performance [5]. In addition, GH upregulates the myocardial expression of
IGF-I mRNA [6]. Besides direct actions of GH, endocrine or autocrine/paracrine effects of locally pro-
duced IGF-I on the cardiovascular system are likely operating as well, thus making it difﬁcult to
differentiate between the direct effects of GH and those IGF-I-mediated [7].
GH and IGF-I receptors expressed in cardiomyocytes are responsible for direct actions of both
hormones on cardiac growth and metabolism. However, the vast majority of the studies have failed to
show direct, IGF-I-independent hypertrophic effects of GH on cardiomyocytes [4]. In contrast, exper-
imental models clearly demonstrated that IGF-I per se causes hypertrophy of cultured rat car-
diomyocytes [8]. The increased cardiac protein synthesis is mainly mediated by the activation of the
phosphatidylinositol 3-kinase (PI3K)eAkt pathway, one of the two major pathways of IGF-I signalling
[9], and by delaying cardiomyocyte apoptosis [10]. GH and IGF-I also have direct effects on myocardial
contractility and cardiac output in both humans and experimental animals. These effects are mediated
by the increasedmRNA expression for speciﬁc muscle proteins, including troponin, myosin light chain-
2, and a-actin [4,5]. GH promotes the shift toward the V3 myosin isoform with lower ATPase activity,
which may decrease the energy demand of the contractile process [4,5,11]. In addition, GH and IGF-I
increase both intracellular calcium content and calcium sensitivity of myoﬁlaments in car-
diomyocytes [4,11]. The endothelial cells have high-afﬁnity binding sites for IGF-I. In particular, the
local production of IGF-I causes endothelial dependent vasodilatation via the stimulation of the nitric
oxide (NO) production [4]. Moreover, IGF-I may cause vasodilatation through non-endothelium-
dependent actions, by increasing the activity of the Naþ, Kþ-ATPase in vascular smooth muscle cells
[12], with possible contribution of increased gene expression of the vascular smooth muscle ATP
sensitive potassium channels [4].
Effects of GHD on cardiovascular risk factors and system in adult patients
The relationship between the GH/IGF-I axis and the cardiovascular system is well conﬁrmed by
cardiac functional and morphological abnormalities presented by patients with both GH excess and
deﬁciency [1e4]. In particular, patients with hypopituitarism have reduced life expectancy, with a 2-
fold higher risk of death for cardiovascular disease compared with healthy controls [13]. It is
conceivable that the excessive glucocorticoids or T4 replacement, or gonadal steroids under-
replacement can potentially contribute to the increased cardiovascular mortality in hypopituitary
patients. Nevertheless, when all other pituitary hormones have been adequately replaced, GHD can be
ultimately considered the underlying determinant for the increased mortality observed in these pa-
tients [2e4,13]. GHD-mediated negative effects on the cardiovascular function are played both directly
on the myocardium and endothelium, and indirectly via increased cardiovascular risk factors, hyper-
coagulability, decreased exercise performance and reduced pulmonary capacity [2e4,14].Please cite this article in press as: Di Somma C, et al.Cardiovascular alterations in adult GH deﬁciency, Best
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heart, which is reversed by GH administration. GHD patients present different abnormalities in
cardiac size and function [2e4]. A signiﬁcant reduction in the thickness of the left ventricular (LV)
posterior wall and of the interventricular septum is reported in both children and adolescents with
GHD and in GHD adults, resulting in a decrease of LV mass index (LVMi) and LV internal diameter in
these patients [2e4]. Other studies showed, however, a similar cardiac function and morphology
between patients developing GHD in adult age (AoGHD) and controls [2e4]. In particular, the
decrease in cardiac mass is uncommon in middle-aged or elderly patients, and even in young pa-
tients with AoGHD, while it can be mainly observed in young patients with childhood-onset (Co)
GHD [16]. Similarly, the so-called hypokinetic syndrome, which is characterized by a decrease in
heart rate and systolic performance, was observed only in young GHD patients with CoGHD [2,3]. It
should be noted that echocardiography is not a method sensitive enough to reveal subtle deﬁciency
in LV performance. Using the equilibrium radionuclide angiography, our group ﬁrst reported an
impairment of LV performance in response to exercise in most adult GHD patients, regardless of age
and age of disease onset [2,3,16]. We found also that cardiac performance was correlated with the GH
status, as a signiﬁcant functional impairment could be evidenced in patients with severe and partial
GHD, but not in non-GHD hypopituitary patients [17].
More recently, Boschetti et al. [18] found in a small sample of GHD patients that the coronary ﬂow
reserve (CFR), an early marker of impaired myocardial microcirculation that may be present before
manifest atherosclerosis and stenosis occur, was signiﬁcantly decreased as compared to matched
controls. Newmethodologies, such as 2D speckle-tracking echocardiography (2DSTE) [19], have proven
to bemore sensitive for the detection of subclinical LV dysfunction in several conditions with preserved
LV ejection fraction (EF) [20,21]. In this regard, Mihaila [22] recently reported that adult GHD have LV
systolic function, assessed by conventional echocardiography, within the normal range, whereas LV
longitudinal, circumferential, and torsion functions, assessed by 2DSTE, were impaired, which is
suggestive of intrinsic myocardial disease in these patients. Thus, the use of traditional methods of
assessment of cardiac impairment might show limited diagnostic accuracy in deﬁning the effects of
GHD on cardiac mass [23]. Cardiac magnetic resonance (CMR) imaging, a reliable and reproducible
technique for measuring myocardial volume, mass and function, has been used to study a range of
cardiomyopathies [24,25]. Currently, there are only few CMR studies assessing the impact of GH
deﬁciency on the heart [26,27,34]. Using CMR, Thomas et al. [27] studied the effects of GHD on
myocardial structure and function and found that AoGHD patients have reduced aortic area and LV
Mass index (Mi) compared to age- and sex matched healthy controls, but both these cardiac indexes
increased after 1 year of GH treatment.
Tipically, adults with GHD have an adverse lipid proﬁle [28]. In particular, increased low-density
lipoprotein (LDL) cholesterol and triglycerides have been documented in both sexes, whereas
decreased high-density lipoprotein (HDL) cholesterol has been showed only in women, although the
increased total cholesterol/HDL ratio occurred both in men and women [28]. Of interest, the severity
and duration of GHD is correlated with the adverse lipid proﬁle, with an inverse association emerging
between IGF-I and LDL-cholesterol levels [2,3]. Contrariwise, no differences in lipoprotein (a) and
apolipoprotein B levels were found between GHD and controls [28,29]. Other cardiovascular risk
factors, including increased homocysteine and C-reactive protein levels (CRP) are present in GHD
patients [29]. In particular, GHD patients have an approximately 4- to 5-fold increase in CRP [29,30],
suggesting the presence of a pro-inﬂammatory state related to GHD [31,32]. Also, other pro-
inﬂammatory factors may be involved in pathophysiological mechanisms of GHD-related cardiovas-
cular complications. Among them, interleukin (IL-6) and tumor necrosis factor (TNF)-a are well known
to play a major role in causing endothelial dysfunction [32]. Increased IL-6 and TNF-a levels have
documented in patients with GHD, independently of BMI or obesity [29]. Recently, it has been observed
that GHD is associated with altered adipokine protein expression pattern and increased adipocyte
diameter, whichmay predisposewhite adipose tissue to hypoxia and adipocyte dysfunction, paving the
way to the development of the low-grade chronic inﬂammation [29,33,34]. Conﬂicting data are
available in the literature on leptin levels in GHD patients, and some studies found that its levels were
higher in GHD patients than in controls [35e37], while others did not [38]. One study in humans also
failed to detect any effect of GH on circulating leptin concentrations [39]. Pregnancy-associated plasmaPlease cite this article in press as: Di Somma C, et al.Cardiovascular alterations in adult GH deﬁciency, Best
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since PAPP-A is both a cardiovascular risk factor and a mediator of IGF-I bioavailability [40].
GHD is associated with changes in body composition, including reduced lean body mass and
increased visceral adiposity [41,42], a phenotype that has been closely linked to insulin resistance and
glucose intolerance. Insulin resistance, determined by a decreased insulin-stimulated glucose uptake
by fat and skeletal muscle, is an important feature of the metabolic syndrome (MetS) and is associated
with low-grade chronic inﬂammation, endothelial dysfunction and increased cardiovascular mortality
[43]. Low, normal and high basal insulin levels have been found in GHD adults, being the degree of
obesity a possible confounding factor [14]. In contrast to patients affected by MetS, signiﬁcantly
elevated insulin levels might be not characteristically observed in patients with GHD. However, using
the hyperinsulinemic euglycemic clamp method, Johansson et al. [44] showed a 2e3-fold reduction in
insulin sensitivity in GHD patients compared with controls, despite normal fasting glucose and insulin
levels. As so far, the prevalence of MetS is increased in GHD patients. van der Klaauw et al. [45]
documented that GHD patients had a more than 2-fold higher prevalence of MetS when compared
with the general population. Also, Attanasio et al. [46] found that MetS prevalence was increased in
GHD patients. Interestingly, lean individuals with GHD have larger waist circumference and more
abdominal adiposity, with a proportional increase in subcutaneous and visceral tissue with respect to
control subjects [33]. Among all these indirect cardiovascular risk factors, abdominal obesity, assessed
simply by waist circumference or waist:hip ratio is a well-known negative predictor of subsequent
coronary artery disease [47]. Patients with GHD were consistently proven to be affected with centrally
distributed adiposity and, additionally, with dyslipidaemia [2e4], the treatment of which becomes
crucial in primary and secondary prevention of cardiovascular disease.
Conﬂicting results have reported in the literature regarding blood pressure (BP) and peripheral
resistance in GHD. On the one side, some studies reported slight increases in BP in GHD patients
[2e4,48]. The association between GHD and altered BP was conﬁrmed by a large study, which mainly
consisted of AoGHD patients without recombinant human rhGH replacement treatment [48]. Similarly,
an observational study recruiting almost 1000 GHD patients reported an increased prevalence of hy-
pertension compared to the general population (22% vs.15%) [49]. Consequently, GHD was found to be
associated with an increased activity of the sympathetic nervous system, with a diastolic BP around
10 mmHg higher in GHD patients than in controls [50]. On the other side, unaltered BP proﬁles were
also reported [51], while BP was even reported to be reduced in young GHD adults [2e4,52]. Likewise, a
study from our group failed to document any increase in the prevalence of hypertension in 56 patients
classiﬁed to have severe GHD compared to sex- and age-matched healthy controls, while showing a
decreased systolic BP at peak physical exercise [17]. While circadian BP patterns have been reported to
be modiﬁed in adult GHD patients [53], a study on 24-h ambulatory BP and circadian rhythm found
signiﬁcant decreases in both systolic and diastolic BP in adult GHD subjects, without any change in
circadian rhythm [54].
Conversely, GHD has been consistently found to be associatedwith vascular endothelial dysfunction
and premature vascular atherosclerosis. A decreased formation of NO is reported to occur in untreated
GHD patients [55] and, because NO plays a key role in regulating endothelial function and in inhibiting
muscle cell proliferation, it is reasonable to hypothesize that a reduced NO synthesis might be
implicated in the endothelial dysfunction of patients with GHD. In fact, patients with GHDwere shown
to have increased carotid intima-media thickness (IMT), one of the earliest morphological changes in
the arterial wall in the process of atherogenesis. Markussis et al. ﬁrstly showed increased carotid IMT
and higher prevalence of atheromatous plaque of common carotid artery in otherwise asymptomatic
GHD patients [51]. Afterwards, the association between GHD and increased carotid IMT and/or
atherosclerotic plaques, as well as vascular endothelial dysfunction, was conﬁrmed in other series of
GHD patients, although with some discrepancies among data [2,3,55,57], likely related to the vari-
ability of IGF-I levels in GHD patients. Indeed, it has been found that only patients with IGF-I levels
below the normal range presented an increased IMT value and well-deﬁned atherosclerotic plaques at
the level of common carotid arteries [2,3]. Although the relationship between premature atheroscle-
rosis and GH and/or IGF-1 deﬁciency is still far to be completely elucidated, it can be postulated that the
presence of IGF-I deﬁciency per se is associated with increased IMT and atherosclerotic plaques at the
level of the carotid arteries. As further ﬁndings, a number of different markers of vascular andPlease cite this article in press as: Di Somma C, et al.Cardiovascular alterations in adult GH deﬁciency, Best
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the aorta and impaired vasodilatory ﬂow [60], disorders in the coagulation and ﬁbrinolytic system
components, and abnormalities in inﬂammatory cardiovascular markers, suggestive of a pro-
thrombotic diathesis [2e4,29]. Notably, some of these abnormalities, mainly hyperﬁbrinogenemia,
ﬁbrinolytic markers, soluble adhesion molecules, and other inﬂammatory cytokines were more pre-
dominant in AoGHD than in CoGHD. Although there is scant evidence on a direct association with the
disease severity [2,3,61], these alterations might contribute to the increased prevalence of cardiovas-
cular diseases associated with GHD and could be considered the possible link between GHD, inﬂam-
mation, and atherosclerosis [29,40].
Effects of rhGH replacement therapy on cardiovascular risk factors and system in adult patients
In spite of existing controversies on cardiovascular impairment of GHD patients, an overall agree-
ment exists in the literature on the ability of GH replacement therapy to improve most cardiovascular
risk factors outlined in adult hypopituitary patients [2e4,29]. However, optimal GH dosing and mo-
dality of treatment are warranted to maximize the beneﬁts of GH therapy and minimise its potential
risks [62].
Robust evidence supports the effectiveness of long-term GH replacement to improve the body
composition. GH replacement produces a gradual increases of lean body mass by 2e5 kg and a
reduction in fat mass by 30% (approximately 4e6 kg of visceral fat) [63]. The gain in lean body mass is
maintained for at least 10 years of GH replacement both in men and women, although the time
necessary to detect signiﬁcant changes may differ between genders. In fact, both men and women lose
most of their fat mass in the ﬁrst year of GH replacement, but men maintained their body weight
unaltered over the next nine years of observation, while women regained fat mass during the sub-
sequent two years, after which fat mass remained unchanged until ten years of therapy [64]. Inter-
estingly, changes in body composition appeared to be at least in part sustained after 15 years of therapy
[65].
According to the Framingham model, the improvement in body composition reﬂects a 3e4%
decrease in the incidence of coronary heart disease over ten years; thus, this effect of GH replacement
therapy represent per se the single most important factor in reducing vascular risk [65].
Nevertheless, it has been suggested that dyslipidaemia is the strongest contributor of the excess in
cardiovascular risk associated with hypopituitarism [28,29]. Abnormalities in serum lipid concentra-
tions improved with GH replacement therapy, and the same applies to impairment in ﬁbrinolysis [62].
A meta-analysis of blinded, randomized, placebo-controlled trials using low doses and long-duration
GH treatment showed that GH replacement has beneﬁcial effects on body composition, total and
LDL cholesterol levels, as well as diastolic blood pressure, without signiﬁcant effects on triglycerides
levels [23]. While the positive effect GH therapy on lipid proﬁle was conﬁrmed in a long-term 15-year
prospective study (65), another 7-yearr study failed to evidence this beneﬁcial effect [66]. In addition to
beneﬁts on serum cholesterol level, GH replacement was shown to improve apolipoprotein B levels in
one study [67], while lipoprotein (a) levels increased during GH treatment in others [67,68]. Never-
theless, these unfavorable changes may be outweighed by the beneﬁcial effects of GH replacement on
total cholesterol and LDL-C levels. Additional beneﬁts on serum lipid levels may be achieved by
combination therapy with GH and statin treatment, and data from KIMS survey suggest that the effect
of the concomitant treatments is additive [69].
Globally considering the effects on body composition and lipid proﬁle, a number of studies conﬁrm
that long-term treatment with GH improves the constellation of metabolic parameters of MetS
[45,46,70e74]. On the other hand, the effects by GH replacement on insulin sensitivity are still debated
[75,76]. This controversy might be partially explained by differences in the duration of treatment
among the studies, as GH replacement seems to further deteriorate insulin sensitivity in the short-
term, namely after 6 weeks; conversely, longer courses of GH treatment were proven to return insu-
lin sensitivity to baseline values through the increase in IGF-1 levels and the reduction of fat bodymass
[2e4]. Accordingly, in a long-term trial, seven-year GH replacement provided protection from the age-
related decline in insulin sensitivity [77]. Among emerging cardiovascular risk factors, it has also re-
ported that GH replacement can improve low-grade inﬂammation, as documented by a reduction inPlease cite this article in press as: Di Somma C, et al.Cardiovascular alterations in adult GH deﬁciency, Best
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Some positive effects of GH replacement can also be observed for adipokines like adiponectin, leptin
[35,36], and pregnancy-associated plasma protein A (PAPP-A), a speciﬁc protease whose substrate is
IGF-I, which is considered as a biological marker of unstable atherosclerotic plaques [29]. In line with
previous studies [79,80], GH replacement exerts positive effects on the sympatho-vagal balance,
endothelial function and blood pressure levels in GHD patients, which might contribute to improve
their atherosclerotic proﬁle.
In several series of adult GHD patients, GH replacement for 6e24 months was associated with
improved IMT at common carotid arteries, reaching levels recorded in controls [2e4,16,56,57], while
withdrawal of GH replacement for 6 months in severe GHD adults, but not in adolescents [2,3], was
associated with an increase in IMT and further impairment of the cardiovascular risk [16]. Moreover,
GH replacement induces a signiﬁcant increase in ﬂow-mediated dilation, a marker of endothelial
function and arterial compliance [2,3]. Cardiac mass is another target of HG therapy and an increase in
LV mass is commonly documented in the early phase of GH replacement therapy of GHD adults
[2e4,2e4,81,82] as well as children [2,3,83e85]. Amato et al. [83] ﬁrst showed that GH replacement
induced a 26% increase in the LVMi and a 12% increase in the LVEF, which disappeared six months after
GH discontinuation. In addition, Ter Maaten et al. [86] found that the hypertrophic effect of GH
replacement was short-lasting also during the treatment, as LV mass returned to normal after two
years, and similar to pretreatment values after ten-year replacement. In seven adults with AoGHD, 42
months of open GH treatment increased the LV mass and decreased the atrial emptying index, which
reﬂects diastolic function, as compared with healthy matched controls [87].
These results suggest also that patients' age might per se promote inappropriate increments in LV
mass during long-term GH replacement. However, it should be noted that the doses of GH replacement
in these studies were higher than that used currently. In effect, the dose employed during the last
decade was reduced from 20 to 26 mg/kg bodyweight in the initial studies to 4e6 mg/kg bodyweight in
modern ones.
Together, studies so far published seem to imply that the beneﬁcial effects of current low-dose GH
regimens may be counterbalanced by potentially harmful effects of initially-used high GH dose,
whereas low-dose individualized GH replacement is effective in improving cardiac function and carries
a lower risk of developing cardiac hypertrophy in the long-term [2e4]. However, if an inappropriately
high dose of GH is given, there is a risk of an unwanted increment in left ventricular mass, particularly
in elderly GHD patients during long-term treatment [2e4].
A few studies did not report any signiﬁcant change in cardiac mass and performance [2e4].
Contrariwise, we observed a signiﬁcant increase of the LVEF at peak exercise after 12 month of GH
replacement in a cohort of young GHD patients, even if exercise-induced changes of LVEF remained
signiﬁcantly lower than controls after treatment [2,3].
Compared to GHD patients who refused GH replacement, only patients receiving GH replacement
showed an improvement of cardiovascular risk parameters, cardiac mass and function parameters after
12 months [2,3]. It should be emphasized, however, that GH replacement, for 12 months is unable to
completely normalize cardiac performance, thus indicating that cardiac performance should be
monitored in long-term studies. In fact, Chrisoulidou et al. [66] reported a decrease of diastolic blood
pressure and an improvement of diastolic ﬁlling persisting seven years after GH replacement.
Summary
GH replacement increases cardiac size, not exceeding normal values, improves cardiac performance,
more evidently on peak exercise, affects positively body composition and lipid proﬁle, and reduces IMT
at common carotid arteries. Despite this large body of evidence on the beneﬁcial effects of GH
replacement in GHD patients, however, the most recent interventional studies failed to consistently
show GH-mediated improvements in cardiac and prognostic outcomes [88e92]. To weight the
beneﬁcial effect of GH replacement in terms of reduced mortality is a relevant clinical issue. Currently,
there is no abundance of data regarding the effect of GH replacement on cardiovascular morbidity and
mortality [2e4,13,93]. Recently, Gazzaruso et al. [29] underpinned the lack of reliable risk markers in
order to attain therapeutic beneﬁt as much as possible by GH replacement, so conﬁrming that morePlease cite this article in press as: Di Somma C, et al.Cardiovascular alterations in adult GH deﬁciency, Best
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that hypertension and age are important components of the natural history of GHD and suggested that
GH replacement optimization and close follow-up of patients with GHD could reduce the cumulative
CV event rates. However, the results of a large registry database showed that GH replacement may be
important in adult GHD not only to improve general health and wellbeing, but also to reduce the risk of
premature mortality [95]. As the individual changes in the cardiovascular risk factors in all the studies
are small and affected by several confounding factors, the global beneﬁt of GH replacement on car-
diovascular mortality remains to be determined.Practice points
 GHD affects heart and the vasculature.
 The role for conventional CV risk factors has not been well established.
 GHD is associated with a number of detrimental factors that affect the cardiovascular system.
 GH replacement improves cardiac size, not exceeding normal values, and cardiac
performance.
 Optimizing GH therapy is mandatory to prevent side effects.
Research agenda
 Studies are required to identify accurate prognosticators of cardiovascular risk.
 Studies are required to evaluate whether new imaging techniques have concrete advantages
for the assessment of cardiovascular system in clinical practice.
 Further prospective and long-term studies are guaranteed to evaluate the effective reduction
of cardiovascular mortality.Conﬂict of interest statement
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